| Literature DB >> 19853657 |
Paula I Moreira1, Xiongwei Zhu, Xinglong Wang, Hyoung-Gon Lee, Akihiko Nunomura, Robert B Petersen, George Perry, Mark A Smith.
Abstract
Mitochondrial dysfunction has long been associated with neurodegenerative disease. Therefore, mitochondrial protective agents represent a unique direction for the development of drug candidates that can modify the pathogenesis of neurodegeneration. This review discusses evidence showing that mitochondrial dysfunction has a central role in the pathogenesis of Alzheimer's, Parkinson's and Huntington's diseases and amyotrophic lateral sclerosis. We also debate the potential therapeutic efficacy of metabolic antioxidants, mitochondria-directed antioxidants and Szeto-Schiller (SS) peptides. Since these compounds preferentially target mitochondria, a major source of oxidative damage, they are promising therapeutic candidates for neurodegenerative diseases. Furthermore, we will briefly discuss the novel action of the antihistamine drug Dimebon on mitochondria.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19853657 PMCID： PMC2790540 DOI： 10.1016/j.bbadis.2009.10.007
Source DB: PubMed Journal: Biochim Biophys Acta ISSN： 0006-3002